2020
Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, Stockhammer P, Lötsch-Gojo D, Gojo J, Gabler L, Spiegl-Kreinecker S, Dome B, Steindl A, Klikovits T, Hoda MA, Jakopovic M, Samarzija M, Mohorcic K, Kern I, Kiesel B, Brcic L, Oberndorfer F, Müllauer L, Klepetko W, Schmidt WM, Kumar R, Hegedus B, Berger W. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. Clinical Cancer Research 2020, 26: 3819-3830. PMID: 32317288, DOI: 10.1158/1078-0432.ccr-19-3573.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorCell Line, TumorCell SurvivalCell Transformation, NeoplasticComparative Genomic HybridizationDisease ProgressionDNA Mutational AnalysisExome SequencingFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMesothelioma, MalignantMiddle AgedMutationPleuraPleural NeoplasmsPrognosisPromoter Regions, GeneticRetrospective StudiesTelomeraseConceptsHuman malignant pleural mesotheliomaMalignant pleural mesotheliomaPromoter mutationsLuciferase promoter assaysGene expression profilingImmortalized cell linesArray comparative genomic hybridizationComparative genomic hybridizationWild-type samplesGene promoterExpression profilingPromoter assaysPromoter activityTelomerase reverse transcriptase gene promoterCell immortalizationMolecular mechanismsMutations/deletionsMalignant transformation processMPM casesSpecific mutation patternsGenomic hybridizationTelomerase activityGenomic alteration patternsMutationsChromosomal alterationsComparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma
Bilecz A, Stockhammer P, Theegarten D, Kern I, Jakopovic M, Samarzija M, Klikovits T, Hoda MA, Döme B, Oberndorfer F, Muellauer L, Fillinger J, Kovács I, Pirker C, Schuler M, Plönes T, Aigner C, Klepetko W, Berger W, Brcic L, Laszlo V, Hegedus B. Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. Histopathology 2020, 77: 55-66. PMID: 32170970, DOI: 10.1111/his.14105.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaEpithelioid malignant pleural mesotheliomaOverall survivalHistological subtypesPleural mesotheliomaIntensive multimodal treatment approachesEpithelioid pleural mesotheliomaIndependent prognostic factorShorter overall survivalHigh nuclear gradeMultimodal treatment approachCancer Genome Atlas (TCGA) databaseNuclear grading systemLonger OSPrognostic factorsPrognostic impactPrognostic roleRare malignancyDismal prognosisTrabecular variantMultimodal treatmentPrognostic significancePatient cohortHistopathologic parametersMultimodal therapy
2019
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma
Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer 2019, 139: 124-132. PMID: 31778960, DOI: 10.1016/j.lungcan.2019.11.013.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaNon-malignant pleural diseasePleural effusionMPM patientsPleural mesotheliomaPrognostic stratificationNon-epithelioid malignant pleural mesotheliomaStage IV lung cancerEpithelioid malignant pleural mesotheliomaInferior overall survivalTGF-β levelsLevels of TGFLung cancer patientsChest CT scanOverall survivalSMRP levelsClinicopathological characteristicsDismal prognosisPleural diseaseTumor loadAggressive malignancyDisease stageCancer patientsLung cancerPrimary diagnosis
2018
The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
Laszlo V, Valko Z, Ozsvar J, Kovacs I, Garay T, Hoda MA, Klikovits T, Stockhammer P, Aigner C, Gröger M, Klepetko W, Berger W, Grusch M, Tovari J, Waizenegger IC, Dome B, Hegedus B. The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. Journal Of Molecular Medicine 2018, 97: 231-242. PMID: 30539198, PMCID: PMC6348072, DOI: 10.1007/s00109-018-1725-7.Peer-Reviewed Original Research
2017
Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda MA, Ghanim B, Opitz I, Frauenfelder T, Nguyen-Kim TDL, Weder W, Berger W, Grusch M, Aigner C, Klepetko W, Dome B, Renyi-Vamos F, Oehler R, Hegedus B. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Scientific Reports 2017, 7: 16456. PMID: 29184132, PMCID: PMC5705645, DOI: 10.1038/s41598-017-16551-7.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaNon-malignant pleural diseasePlasma C4d levelsC4d levelsHealthy volunteersInduction chemotherapyMPM patientsPleural mesotheliomaTumor volumeMultivariate Cox regression modelEctopic lymphoid structuresBetter overall survivalCox regression modelHigher tumor volumeNew prognostic biomarkerPlasma C4dOverall survivalProgressive diseaseLymphoid structuresPleural diseaseC4d immunohistochemistryPrognostic biomarkerTumor stromaPatientsChemotherapeutic response
2016
Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study
Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study. European Journal Of Cancer 2016, 63: 64-73. PMID: 27288871, DOI: 10.1016/j.ejca.2016.04.018.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaActivin A levelsMPM patientsActivin APleural mesotheliomaHigh activin A levelsNon-malignant pleural diseaseEpithelioid malignant pleural mesotheliomaEpithelioid MPM patientsTime of diagnosisLonger overall survivalNovel prognostic biomarkerMulti-institutional studyEnzyme-linked immunosorbent assayA levelsPlasma activinOverall survivalSurgical resectionActivin expressionHigh activinPleural diseasePoor prognosisClinicopathological variablesEpithelioid histologyHealthy controls